Literature DB >> 24423480

Outcomes of open surgical repair for chronic type B aortic dissections.

Allan M Conway1, Mostafa Sadek2, Joanelle Lugo2, Jain B Pillai2, Yonni Pellet2, Georgia Panagopoulos2, Alfio Carroccio2, Konstadinos Plestis2.   

Abstract

OBJECTIVE: Open surgical repair (OSR) for chronic type B aortic dissection (CTBAD) has an associated morbidity and mortality. The role of thoracic endovascular aortic repair (TEVAR) in CTBAD has not been determined. We analyzed our contemporary experience of CTBAD undergoing OSR to identify high-risk patients who may be considered for TEVAR.
METHODS: From 1999 to 2010, 221 patients had repair of descending thoracic and thoracoabdominal aortic aneurysms, including 86 patients with CTBADs. We analyzed this cohort for mortality, complications, length of stay, and reinterventions.
RESULTS: OSR was performed in 25 (29%) and 61 (71%) patients for descending thoracic and thoracoabdominal CTBAD, respectively. Median age was 57.0 years (interquartile range [IQR], 52.0-64.2 years), and median diameter was 6.0 cm (IQR, 5.0-6.9 cm). Fifty-nine patients (69%) were male. Eight (9%) were treated for rupture. Follow-up duration was 4.6 years (IQR, 2.8-6.9 years). Hospital mortality occurred in five patients (5.8%). Cardiopulmonary bypass was used in 83 patients (97%) and deep hypothermic arrest in 36 (42%). Two patients (2.3%) each developed paraplegia, stroke, and renal failure requiring permanent hemodialysis in the postoperative period. Length of stay was 13.5 days (IQR, 10.0-21.0 days). Univariate predictors of hospital death included redo operations and prolonged pump time (P < .05). Six patients (7%) had aortic-related reoperations at 4.3 years (IQR, 2.7-5.2 years): one for an ascending aortic aneurysm and five for descending aortic aneurysms. Overall survival at 1, 5, and 7 years was 92%, 83%, and 70%, respectively, and freedom from reoperation was 99%, 90%, and 86%, respectively.
CONCLUSIONS: OSR of CTBAD is a durable option with low mortality. Patients requiring redo operations or anticipated prolonged pump time need further evaluation to determine whether conventional OSR or TEVAR, if feasible, is the optimal treatment option.
Copyright © 2014 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24423480     DOI: 10.1016/j.jvs.2013.11.002

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  Open surgical repair for chronic type B aortic dissection: a systematic review.

Authors:  David H Tian; Ramesh P De Silva; Tom Wang; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2014-07

2.  Open repair of chronic complicated type B aortic dissection using the open distal technique.

Authors:  Anthony L Estrera; Harleen Sandhu; Rana O Afifi; Ali Azizzadeh; Kristofer Charlton-Ouw; Charles C Miller; Hazim J Safi
Journal:  Ann Cardiothorac Surg       Date:  2014-07

3.  Conservative management versus endovascular or open surgery in the spectrum of type B aortic dissection.

Authors:  Xun Yuan; Andreas Mitsis; Mohammed Ghonem; Ilias Iakovakis; Christoph A Nienaber
Journal:  J Vis Surg       Date:  2018-03-23

4.  Open repair remains the gold standard.

Authors:  Jonathan C Hong; Joseph S Coselli
Journal:  JTCVS Tech       Date:  2021-01-26

5.  Descending thoracic aortic repair outcomes for chronic aortic dissection: a single-centre experience.

Authors:  Yoshitaka Yamane; Susumu Oshima; Kazumasa Ishiko; Makoto Okiyama; Tomohiro Hirokami; Yuki Hirai; Shigeru Sakurai; Kensuke Ozaki; Kenichi Yoshimura; Shinya Takahashi; Shin Yamamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09

6.  Contemporary Management Strategies for Chronic Type B Aortic Dissections: A Systematic Review.

Authors:  Arnoud V Kamman; Hector W L de Beaufort; Guido H W van Bogerijen; Foeke J H Nauta; Robin H Heijmen; Frans L Moll; Joost A van Herwaarden; Santi Trimarchi
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.